See the DrugPatentWatch profile for Pifeltro
What drug class is Pifeltro?
Pifeltro (doravirine) is an HIV antiretroviral medication in the non-nucleoside reverse transcriptase inhibitor (NNRTI) drug class. It works by blocking HIV reverse transcriptase, an enzyme the virus needs to replicate.
How does the NNRTI class differ from other HIV drug classes?
NNRTIs like doravirine inhibit HIV reverse transcriptase at a different site than nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). That difference matters because it changes how the drugs suppress viral replication and how resistance can develop, but the end goal is the same: stopping HIV from reproducing.
What’s Pifeltro typically used with?
Pifeltro is used as part of an antiretroviral regimen for HIV treatment rather than as a standalone therapy, because standard HIV care combines drugs from different classes to improve viral suppression and reduce the chance of resistance.
Are there other common NNRTIs similar to Pifeltro?
Yes. The NNRTI class includes other well-known drugs used in HIV regimens, such as efavirenz and rilpivirine (and older agents like nevirapine). Pifeltro is one option within that same NNRTI category.
Patent and manufacturer info (if you’re researching exclusivity)
If you’re looking for company/patent detail on doravirine (Pifeltro), DrugPatentWatch tracks patent and exclusivity information. You can check it here: https://www.drugpatentwatch.com/pifeltro
Sources
- DrugPatentWatch: https://www.drugpatentwatch.com/pifeltro